Emerging therapies for MASLD and their impact on plasma lipids

Emerging therapies for MASLD and their impact on plasma lipids

Metabolic-dysfunction associated steatotic liver disease (MASLD) affects 1 out of every 3 individuals in the adult population and the disease prevalence is predicted to increase worldwide. Patients with MASLD are also burdened by cardiovascular disease, which is the leading cause of mortality in thi...

Full description

Bibliographic Details
Main Authors: Madison Nguyen, Amon Asgharpour, Dave L. Dixon, Arun J. Sanyal, Anurag Mehta
Format: Article
Language:English
Published: Elsevier 2024-03-01
Series:American Journal of Preventive Cardiology
Subjects:
Metabolic-dysfunction associated steatotic liver disease
Metabolic-dysfunction associated steatohepatitis
Dyslipidemia
Cardiometabolic disease
Atherosclerosis
Online Access:http://www.sciencedirect.com/science/article/pii/S2666667724000060

Internet

http://www.sciencedirect.com/science/article/pii/S2666667724000060

Similar Items